+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Targeted Therapies"

Epigenetic Therapeutics: Global Markets - Product Thumbnail Image

Epigenetic Therapeutics: Global Markets

  • Report
  • June 2023
  • 155 Pages
  • Global
From
Aptamer-Drug Conjugates Market - Global Forecast 2025-2030 - Product Thumbnail Image

Aptamer-Drug Conjugates Market - Global Forecast 2025-2030

  • Report
  • August 2025
  • 196 Pages
  • Global
From
GalNac Conjugates Market - Global Forecast 2025-2030 - Product Thumbnail Image

GalNac Conjugates Market - Global Forecast 2025-2030

  • Report
  • August 2025
  • 190 Pages
  • Global
From
From
From
Aptamer CDMO Market - Global Forecast 2025-2030 - Product Thumbnail Image

Aptamer CDMO Market - Global Forecast 2025-2030

  • Report
  • August 2025
  • 182 Pages
  • Global
From
From
From
From
Biologic Peptide API Market - Global Forecast 2025-2030 - Product Thumbnail Image

Biologic Peptide API Market - Global Forecast 2025-2030

  • Report
  • August 2025
  • 192 Pages
  • Global
From
From
From
From
From
From
Loading Indicator

The Targeted Therapies market within the context of Genomics is focused on the development of treatments that target specific genetic mutations or pathways. These therapies are designed to be more effective and have fewer side effects than traditional treatments. Genomics has enabled the development of personalized treatments that are tailored to the individual patient's genetic makeup. This has allowed for the development of drugs that target specific mutations or pathways, leading to more effective treatments. The Targeted Therapies market is a rapidly growing field, with many companies investing in research and development. Companies such as Gilead Sciences, Novartis, and AstraZeneca are leading the way in the development of targeted therapies. Other companies such as Merck, Pfizer, and Roche are also investing in the development of targeted therapies. Show Less Read more